Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors

Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors

Conditions: Healthy Volunteers; Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer (NSCLC); Esophageal Squamous Cell Carcinoma; Cervical Cancer; Endometrial Cancer; Ovarian Cancer
Interventions: Drug: RAD301 ([68Ga]-RAD301)
Sponsors: Radiopharm Theranostics, Ltd
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 25, 2025Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments